INOVIO PHARMACEUTICALS INC's ticker is INO and the CUSIP is 45773H201. A total of 75 filers reported holding INOVIO PHARMACEUTICALS INC in Q2 2014. The put-call ratio across all filers is 3.88 and the average weighting 0.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $7,284 | -21.2% | 18,723 | -9.5% | 0.00% | – |
Q2 2023 | $9,242 | -97.5% | 20,698 | -95.3% | 0.00% | – |
Q1 2023 | $363,510 | +1087.4% | 443,304 | +2159.0% | 0.00% | – |
Q4 2022 | $30,613 | -49.0% | 19,624 | -43.7% | 0.00% | – |
Q3 2022 | $60,000 | -15.5% | 34,844 | -14.6% | 0.00% | – |
Q2 2022 | $71,000 | -79.9% | 40,808 | -58.6% | 0.00% | – |
Q1 2022 | $354,000 | -70.7% | 98,598 | -59.3% | 0.00% | – |
Q4 2021 | $1,207,000 | -13.9% | 241,972 | +23.7% | 0.00% | – |
Q3 2021 | $1,402,000 | +19.3% | 195,658 | +54.2% | 0.00% | – |
Q2 2021 | $1,175,000 | +5.6% | 126,883 | +5.8% | 0.00% | – |
Q1 2021 | $1,113,000 | -69.8% | 119,912 | -71.3% | 0.00% | -100.0% |
Q4 2020 | $3,691,000 | -18.1% | 417,089 | +7.3% | 0.00% | 0.0% |
Q3 2020 | $4,508,000 | -59.5% | 388,688 | -6.1% | 0.00% | -66.7% |
Q2 2020 | $11,131,000 | +1727.8% | 413,887 | +405.4% | 0.00% | – |
Q1 2020 | $609,000 | +127.2% | 81,892 | +1.0% | 0.00% | – |
Q4 2019 | $268,000 | -33.2% | 81,102 | -58.6% | 0.00% | – |
Q3 2019 | $401,000 | -27.9% | 195,718 | +3.5% | 0.00% | – |
Q2 2019 | $556,000 | -43.1% | 189,094 | -27.9% | 0.00% | – |
Q1 2019 | $978,000 | +46.0% | 262,197 | +56.5% | 0.00% | – |
Q4 2018 | $670,000 | +54.4% | 167,493 | +115.0% | 0.00% | – |
Q3 2018 | $434,000 | +46.6% | 77,921 | +3.2% | 0.00% | – |
Q2 2018 | $296,000 | -65.5% | 75,523 | -58.5% | 0.00% | – |
Q1 2018 | $857,000 | +16.0% | 181,875 | +1.6% | 0.00% | – |
Q4 2017 | $739,000 | +12.5% | 179,008 | +72.7% | 0.00% | – |
Q3 2017 | $657,000 | -6.3% | 103,680 | +16.1% | 0.00% | – |
Q2 2017 | $701,000 | -15.0% | 89,338 | -28.3% | 0.00% | – |
Q1 2017 | $825,000 | +23.0% | 124,565 | +28.9% | 0.00% | – |
Q4 2016 | $671,000 | -12.3% | 96,667 | +17.7% | 0.00% | – |
Q3 2016 | $765,000 | +1.1% | 82,117 | +0.2% | 0.00% | – |
Q2 2016 | $757,000 | +9.2% | 81,923 | +3.1% | 0.00% | – |
Q1 2016 | $693,000 | +42.3% | 79,433 | +9.5% | 0.00% | – |
Q4 2015 | $487,000 | +28.5% | 72,546 | +10.5% | 0.00% | – |
Q3 2015 | $379,000 | -29.6% | 65,670 | -0.5% | 0.00% | – |
Q2 2015 | $538,000 | -32.1% | 65,967 | -32.1% | 0.00% | – |
Q1 2015 | $792,000 | +2946.2% | 97,126 | +3380.0% | 0.00% | – |
Q4 2014 | $26,000 | -18.8% | 2,791 | -14.6% | 0.00% | – |
Q3 2014 | $32,000 | -64.4% | 3,269 | -61.1% | 0.00% | – |
Q2 2014 | $90,000 | – | 8,393 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
CAXTON ASSOCIATES LP | 784,679 | $643,437 | 0.10% |
Green Alpha Advisors, LLC | 146,300 | $119,966 | 0.08% |
Virtus ETF Advisers LLC | 54,106 | $44,367 | 0.02% |
Cedar Brook Financial Partners, LLC | 104,881 | $86,002 | 0.02% |
PROFUND ADVISORS LLC | 418,749 | $343,374 | 0.02% |
Arlington Capital Management, Inc. | 27,735 | $22,743 | 0.02% |
Hennion & Walsh Asset Management, Inc. | 382,158 | $313 | 0.02% |
Rafferty Asset Management, LLC | 2,647,927 | $2,171,300 | 0.02% |
Brainard Capital Management LLC | 16,666 | $13,666 | 0.01% |
Beck Bode, LLC | 41,218 | $33,799 | 0.01% |